Navigation Links
Experimental drug boosts survival in recurrent ovarian cancer
Date:9/27/2007

BIRMINGHAM, Ala. New clinical data showed an experimental drug called pertuzumab prolonged the survival time for women with recurrent ovarian cancer, a University of Alabama at Birmingham doctor said recently.

The data was presented Sept. 24 during a scientific session of the 14th European Cancer Conference held in Barcelona, Spain. The sessions main speaker was Sharmila Makhija, M.D., an associate professor in UABs Division of Gynecologic Oncology.

Makhija said Phase II clinical trial data showed that pertuzumab added weeks to the lives of Stage 3 ovarian cancer patients whose disease had returned after treatment with existing chemotherapy regimens.

In the study, pertuzumab was administered in combination with a standard chemotherapy agent sometime after the initial treatments had been given, and after the re-emergence of cancer. Makhija said the new combination added weeks to the standard survival period for recurrent patients, and the drug combo was well-tolerated by the body and caused minimal side effects.

"We wanted to know if pertuzumab would improve the effects of the chemotherapy with cancer recurrence, and if it would improve their lives. It did," Makhija said. "Now we want to see if it impacts overall survival."

Once ovarian cancer becomes resistant to multiple types of chemotherapy, fewer treatment options exist and the focus becomes lengthening patients survival periods.

The pertuzumab trial included 130 women enrolled by UAB, Dana-Farber Cancer Institute and Dana-Farber/Brigham and Women's Cancer Center in Boston, University of Kentucky Chandler Medical Centers Markey Cancer Center in Lexington, Women and Infants Hospital of Rhode Island in Providence, Sharp Rees-Stealy Medical Group in San Diego, University of Oklahoma Health Sciences Center in Oklahoma City. Study costs were paid by Genentech Inc. in South San Francisco, Calif.

Makhija presented the same results earlier this year at the 2007 American Society of Clinical Oncology meeting in Chicago.

Makhija said the Phase II study is now closed, and researchers are in the planning stages for a larger Phase 3 study of pertuzumab set to include hundreds of U.S. women.

Pertuzumab is approved only for experimental uses. It falls within a class of anticancer agents called monoclonal antibodies. Such drugs target key signaling pathways within cells that can stop or slow tumor growth.


'/>"/>

Contact: Troy Goodman
tdgoodman@uab.edu
205-934-8938
University of Alabama at Birmingham
Source:Eurekalert

Related medicine news :

1. Experimental treatment for Ebola Virus Shows promising results in mice
2. FDA approves Phase 0 trial which tests experimental drugs on humans
3. Experimental drug to fight flu
4. Experimental SARS Vaccine
5. Experimental vaccine for shingles is effective
6. Experimental Blood Test May Spot Heart Attack Risk, Study Says
7. Five AIDS Patients To Receive Experimental Anti-retroviral Drugs
8. TMC 114 and 125 experimental drugs to be tested on four HIV patients
9. Protection against HIV and Herpes is possible with the Experimental Microbicide
10. Experimental Therapy Effective Against Malignant Melanoma in Horses
11. Experimental Alzheimer’s Drug curbs the disease in mic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... December 07, 2016 , ... One of two inventors from Glen Burnie, Md., ... painful for her. "This is why the co-inventor and I have designed a new ... then created a prototype of the patent-pending AV-AIR, a device that serves as an ...
(Date:12/7/2016)... ... December 07, 2016 , ... A. Kevin Spann Insurance, ... families throughout the Five Boroughs, is launching a charity drive to raise funds that ... the traditions and spirit of marines and Navy FMF Corpsmen. Working closely with the ...
(Date:12/7/2016)... ... ... Sharon Kleyne, host of the nationally syndicated radio program, The Sharon Kleyne ... declared on her radio program in November 2016 the need to educate people about ... leaders in corporate America, they are trying to take advantage of successful algorithms and ...
(Date:12/7/2016)... ... December 07, 2016 , ... Facial plastic surgeon, Dr. John ... by donating a portion of proceeds to two local organizations: North Chicago Animal Control ... & Friends is a team of authorized and trained volunteers who support rescued ...
(Date:12/7/2016)... ... December 07, 2016 , ... Texas Premier ... operations" carried out by unethical locksmith companies and is urging Search Engines to ... According to Texas Premier Locksmith, these fraudulent locksmith services take advantage of consumers ...
Breaking Medicine News(10 mins):
(Date:12/6/2016)... , Dec. 6, 2016   AlloSource ... cartilage, cellular, bone, skin and soft-tissue allografts for ... , Business Process Manager, for being named to ... Baldrige National Quality Award by the Commerce Department,s ... the organization,s commitment to process excellence. The Baldrige ...
(Date:12/6/2016)... BOSTON , Dec. 6, 2016  BTL ... evaluation proving that its BTL Vanquish ME device ... homogenous energy delivery to the targeted tissue. The ... reduction, 53% higher, with BTL Vanquish ME versus ... providing our physician network and their patients with ...
(Date:12/6/2016)... opioids commonly used for pain management for workplace injuries, employers now ... to nationwide fatalities. The synthetic opioid called U-47700, or ... morphine, resulting in likelihood of addiction, abuse or death. ... , , ... for HMC HealthWorks, explained the opioid drug is less expensive yet ...
Breaking Medicine Technology: